Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 600

1.

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2019 Aug 19;119:97-106. doi: 10.1016/j.ejca.2019.07.016. [Epub ahead of print]

PMID:
31437754
2.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.

Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K.

PLoS One. 2019 Aug 16;14(8):e0221301. doi: 10.1371/journal.pone.0221301. eCollection 2019.

3.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
4.

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.

Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, Sharma A, Garbe C, Singh P, Mehnert JM.

Br J Cancer. 2019 Jul 29. doi: 10.1038/s41416-019-0530-6. [Epub ahead of print]

PMID:
31353364
5.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I.

J Transl Med. 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z.

6.

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.

Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S.

J Immunother Cancer. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0.

7.

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, Bataille V, Marmol VD, Dummer R, Harwood CA, Hauschild A, Höller C, Haedersdal M, Malvehy J, Middleton MR, Morton CA, Nagore E, Stratigos AJ, Szeimies RM, Tagliaferri L, Trakatelli M, Zalaudek I, Eggermont A, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6.

PMID:
31288208
8.

S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018.

Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H, Bauer S, Grabbe S.

J Dtsch Dermatol Ges. 2019 Jun;17(6):663-668. doi: 10.1111/ddg.13849_g.

PMID:
31241846
9.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
10.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
11.

S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018.

Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H, Bauer S, Grabbe S.

J Dtsch Dermatol Ges. 2019 Jun;17(6):663-668. doi: 10.1111/ddg.13849. Epub 2019 May 22.

PMID:
31115967
12.

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, Zalaudek I, Hoeller C, Dummer R, Forsea AM, Kandolf-Sekulovic L, Olah J, Arenberger P, Bylaite-Bucinskiene M, Vieira R, Middleton M, Levy A, Eggermont AM, Battistella M, Spano JP, Grob JJ, Pages C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Jun;114:117-127. doi: 10.1016/j.ejca.2018.12.036. Epub 2019 May 13.

PMID:
31096150
13.

Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement?

Bier G, Klumpp B, Roder C, Garbe C, Preibsch H, Ernemann U, Hempel JM.

Neuroradiology. 2019 Jul;61(7):775-782. doi: 10.1007/s00234-019-02215-y. Epub 2019 Apr 18.

PMID:
31001647
14.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.

15.

Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.

Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Varey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, Scolyer RA, Garbe C, Stratigos AJ.

J Natl Cancer Inst. 2019 Mar 13. pii: djz034. doi: 10.1093/jnci/djz034. [Epub ahead of print]

PMID:
30863861
16.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A.

Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.

PMID:
30824584
17.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
18.

Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Keim U, Leiter U, Eigentler TK, Röcken M, Gesierich A, Moritz RKC, Heinzerling L, Tüting T, Wollina U, Garbe C.

J Am Acad Dermatol. 2019 May;80(5):1299-1307.e7. doi: 10.1016/j.jaad.2019.01.044. Epub 2019 Jan 29.

PMID:
30703453
19.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
20.

Kein Überlebensvorteil beim Sentinel-Lymphknoten-positiven Melanom mit sofortiger kompletter Lymphadenektomie - eine Übersicht.

Stadler R, Leiter U, Garbe C.

J Dtsch Dermatol Ges. 2019 Jan;17(1):7-14. doi: 10.1111/ddg.13707_g. Review. No abstract available.

PMID:
30615282
21.

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.

Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A.

Immunotherapy. 2019 Mar;11(4):297-309. doi: 10.2217/imt-2018-0149. Epub 2019 Jan 4.

PMID:
30606066
22.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
23.

Modifiable Risk-factors for Keratinocyte Cancers in Australia: A Case-control Study.

Serna-Higuita LM, Harrison SL, Buttner P, Glasby M, Raasch BA, Iftner A, Garbe C, Martus P, Iftner T.

Acta Derm Venereol. 2019 Apr 1;99(4):404-411. doi: 10.2340/00015555-3107.

24.

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D.

Lancet Oncol. 2018 Dec;19(12):e720-e725. doi: 10.1016/S1470-2045(18)30596-5. Review.

PMID:
30507438
25.

Lack of survival benefit in sentinel lymph node-positive melanoma with immediate complete lymphadenectomy - a review.

Stadler R, Leiter U, Garbe C.

J Dtsch Dermatol Ges. 2019 Jan;17(1):7-13. doi: 10.1111/ddg.13707. Epub 2018 Dec 3. Review.

PMID:
30506865
26.

6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.

Venturelli S, Niessner H, Sinnberg T, Berger A, Burkard M, Urmann C, Donaubauer K, Böcker A, Leischner C, Riepl H, Frank J, Lauer UM, Garbe C, Busch C.

Cell Physiol Biochem. 2018;51(2):543-556. doi: 10.1159/000495275. Epub 2018 Nov 20.

27.

BRAF mutation testing in melanoma: results from a German observational multicenter study.

Hartmann A, Schirmacher P, Sterlacci W, Koch W, Liesenfeld DB, Schif B, Garbe C.

Virchows Arch. 2019 Jan;474(1):71-78. doi: 10.1007/s00428-018-2480-4. Epub 2018 Nov 7.

PMID:
30406424
28.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.

Eur J Cancer. 2018 Nov;104:201-209. doi: 10.1016/j.ejca.2018.09.013. Epub 2018 Oct 31.

PMID:
30388700
29.

Time trends in incidence and mortality of cutaneous melanoma in Germany.

Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, Martus P, Leiter U.

J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1272-1280. doi: 10.1111/jdv.15322. Epub 2019 Apr 17.

PMID:
30387899
30.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
31.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
32.

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B.

Cancer Immunol Immunother. 2018 Dec;67(12):1845-1851. doi: 10.1007/s00262-018-2244-7. Epub 2018 Sep 14.

PMID:
30218171
33.

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.

Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X.

Ann Oncol. 2018 Nov 1;29(11):2208-2213. doi: 10.1093/annonc/mdy408.

34.

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.

Makino E, Gutmann V, Kosnopfel C, Niessner H, Forschner A, Garbe C, Sinnberg T, Schittek B.

Cell Death Dis. 2018 Sep 11;9(9):930. doi: 10.1038/s41419-018-0952-8.

35.

Local interventions for actinic keratosis in organ transplant recipients: a systematic review.

Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, Berking C.

Br J Dermatol. 2019 Jan;180(1):43-50. doi: 10.1111/bjd.17148. Epub 2018 Oct 31. Review.

PMID:
30188570
36.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12901. doi: 10.1111/ecc.12901. Epub 2018 Aug 20.

PMID:
30126009
37.

Vemurafenib.

Garbe C, Eigentler TK.

Recent Results Cancer Res. 2018;211:77-89. doi: 10.1007/978-3-319-91442-8_6. Review.

PMID:
30069761
38.

Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Stec T, Keim U, Leiter U, Eigentler TK, Metzler G, Garbe C.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):63-70. doi: 10.1111/jdv.15194. Epub 2018 Aug 14.

PMID:
30051517
39.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

40.

Quality assurance in melanoma care: The EU-MELACARE study.

Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningen S, Louwman M, Robsahm TE, Rutkwoski P, van Akkooi A, Zorzi M, Pasquali S, van de Velde C, Rossi CR.

Eur J Surg Oncol. 2018 Nov;44(11):1773-1778. doi: 10.1016/j.ejso.2018.06.020. Epub 2018 Jul 3.

PMID:
30001892
41.

Patientenakzeptanz und -vertrauen in die automatisierte, computergestützte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie.

Fink C, Uhlmann L, Hofmann M, Forschner A, Eigentler T, Garbe C, Enk A, Haenssle HA.

J Dtsch Dermatol Ges. 2018 Jul;16(7):854-860. doi: 10.1111/ddg.13562_g. No abstract available.

PMID:
29989363
42.

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.

Wagner NB, Forschner A, Leiter U, Garbe C, Eigentler TK.

Br J Cancer. 2018 Aug;119(3):339-346. doi: 10.1038/s41416-018-0167-x. Epub 2018 Jun 28.

43.

Patient acceptance and trust in automated computer-assisted diagnosis of melanoma with dermatofluoroscopy.

Fink C, Uhlmann L, Hofmann M, Forschner A, Eigentler T, Garbe C, Enk A, Haenssle HA.

J Dtsch Dermatol Ges. 2018 Jul;16(7):854-859. doi: 10.1111/ddg.13562. Epub 2018 Jun 21.

PMID:
29927518
44.

YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.

Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, Forchhammer S, Grimmel C, Mertens PR, Hailfinger S, Dunn SE, Garbe C, Schittek B.

Mol Cancer Res. 2018 Jul;16(7):1149-1160. doi: 10.1158/1541-7786.MCR-17-0528. Epub 2018 May 9.

45.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 Jun 7;7(6). pii: bio032656. doi: 10.1242/bio.032656.

46.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
47.

Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions.

Forschner A, Keim U, Hofmann M, Spänkuch I, Lomberg D, Weide B, Tampouri I, Eigentler T, Fink C, Garbe C, Haenssle HA.

Br J Dermatol. 2018 Aug;179(2):478-485. doi: 10.1111/bjd.16565. Epub 2018 Jun 7.

PMID:
29569229
48.

The iris signal: blue periphery, tan collaret and freckles pattern - strong indicators for epidermal skin cancer in South-Eastern Europe.

Grigore M, Furtunescu F, Minca D, Costache M, Garbe C, Simionescu O.

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1662-1667. doi: 10.1111/jdv.14929. Epub 2018 Mar 30.

PMID:
29524265
49.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

50.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

Supplemental Content

Support Center